FluoretiQ patent granted to enable fast and accurate antibiotic testing

FluoretiQ founders smiling with technology on PC

Bristol-based biotech company, FluoretiQ, who is developing fast and accurate point-of-care testing for Urinary Tract Infections (UTIs) and Sexually Transmitted Diseases (STDs), has taken a significant step forward after having a key patent granted. The University of Bristol spinout joined our incubation programme in 2021 with the vision of enabling more targeted antibiotic use and mitigating…

Read More

GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment

GenomeKey blood sample in lab

GenomeKey has been awarded a major grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device. The Bristol-based company joined our incubation programme in 2020 with a vision to build an in vitro diagnostic device that would completely transform the way we diagnose and treat sepsis…

Read More

FluoretiQ announces the closure of £1.1 million funding round

Our member and University of Bristol spin-out, FluoretiQ, has today announced the completion of a £1.1 million, pre-series A investment. Their pioneering NANOPLEX technology is a 15-minute proprietary diagnostic platform for bacterial infections.   The round was led by early-stage life science investors, Deepbridge Capital LLP, with significant participation from MAINStream, OION, SAIC and existing investors. This…

Read More

FluoretiQ case study: Revolutionising bacterial diagnostics

To help our aspiring entrepreneurs and future SETsquared Bristol members, we showcase member and alumni case studies demonstrating the breadth of tech at SETsquared Bristol and what it takes to achieve success. We had a chat with FluoretiQ Co-founder and CEO, Neciah Dorh… FluoretiQ Key Facts Start date: 2 March 2017 Market sector: Healthcare (Diagnostics) Location:  Bristol Number of employees: 10…

Read More

GenomeKey case study: Saving lives through early diagnosis of sepsis

To help our aspiring entrepreneurs and future SETsquared Bristol members, we showcase member and alumni case studies demonstrating the breadth of tech at SETsquared Bristol and what it takes to achieve success. We had a chat with GenomeKey CEO, Michael Roberts… GenomeKey Facts Start date:  August 2019 Market sector: Medtech/diagnostics Location: Bristol Number of employees: 9 growing to 12 and beyond Amount…

Read More